---
title: "Jiangsu Nhwa Pharmaceutical Co., Ltd. (002262.SZ)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002262.SZ.md"
symbol: "002262.SZ"
name: "Jiangsu Nhwa Pharmaceutical Co., Ltd."
industry: "Pharmaceuticals"
datetime: "2026-05-20T04:26:48.315Z"
locales:
  - [en](https://longbridge.com/en/quote/002262.SZ.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002262.SZ.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002262.SZ.md)
---

# Jiangsu Nhwa Pharmaceutical Co., Ltd. (002262.SZ)

## Company Overview

Jiangsu Nhwa Pharmaceutical Co., LTD engages in research, development, production, and sale of central nervous system products in China. The company offers APIs, solid preparation, water injection, and freeze-dried powder formulations for depression, anxiety disorders, insomnia, severe mental disorders, and neurodegenerative diseases. Its products include sufentanil citrate injection, oxaliplatin fumarate injection, alfentanil hydrochloride injection, oxycodone hydrochloride injection, olanzapine tablets, midazolam hydrochloride oral solution, clonazepam injection, lacosamide injection, micuronium injection, pregabalin capsules, vortioxetine hydrobromide tablets, tapentadone hydrochloride tablets, and oxycodone hydrochloride extended-release tablets. The company was founded in 1978 and is headquartered in Xuzhou, China.

| Item | Detail |
|------|--------|
| Industry | Pharmaceuticals |
| Exchange | CN Market |
| Website | [www.nhwa-group.com](https://www.nhwa-group.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: B
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 2026-05-19T04:30:08.000Z

**Overall: B (0.33)**

**Industry**: Pharmaceuticals

| Metric | Value |
|--------|-------|
| Industry Ranking | 12 / 215 |
| Industry Median | C |
| Industry Average | C |

- **Style**: Value - Stocks where the company's main business is in a mature stage.
- **Scale**: Mid - The company has stable operation of a large-cap stock and the high return of a small-cap stock.

**Multi Score**: B

#### Style Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Revenue YoY | 2.73% |  |
| Net Profit YoY | -8.90% |  |
| P/B Ratio | 2.50 |  |
| Dividend Ratio | 0.00% |  |

#### Size Score Score: 

| Indicator | Value | Rating |
|-----------|-------|--------|
| Market Cap | 20874777354.70 |  |
| Revenue | 6004812195.61 |  |

#### Multi Score Score: B

| Indicator | Value | Rating |
|-----------|-------|--------|
| ROE | 13.43% | B |
| Profit Margin | 17.87% | A |
| Gross Margin | 70.97% | A |
| Revenue YoY | 2.73% | C |
| Net Profit YoY | -8.90% | D |
| Total Assets YoY | 8.72% | B |
| Net Assets YoY | 9.91% | B |
| Cash Flow Margin | 85.37% | C |
| OCF YoY | 2.73% | C |
| Turnover | 0.65 | B |
| Gearing Ratio | 13.45% | A |

```chart-data:radar
{
  "title": "Longbridge Financial Score - Jiangsu Nhwa Pharmaceutical Co., Ltd.",
  "chart_type": "radar",
  "dimensions": [
    {
      "name": "Style Score",
      "grade": "",
      "indicators": [
        {
          "name": "Revenue YoY",
          "value": "2.73%",
          "rating": ""
        },
        {
          "name": "Net Profit YoY",
          "value": "-8.90%",
          "rating": ""
        },
        {
          "name": "P/B Ratio",
          "value": "2.50",
          "rating": ""
        },
        {
          "name": "Dividend Ratio",
          "value": "0.00%",
          "rating": ""
        }
      ]
    },
    {
      "name": "Size Score",
      "grade": "",
      "indicators": [
        {
          "name": "Market Cap",
          "value": "20874777354.70",
          "rating": ""
        },
        {
          "name": "Revenue",
          "value": "6004812195.61",
          "rating": ""
        }
      ]
    },
    {
      "name": "Multi Score",
      "grade": "B",
      "indicators": [
        {
          "name": "ROE",
          "value": "13.43%",
          "rating": "B"
        },
        {
          "name": "Profit Margin",
          "value": "17.87%",
          "rating": "A"
        },
        {
          "name": "Gross Margin",
          "value": "70.97%",
          "rating": "A"
        },
        {
          "name": "Revenue YoY",
          "value": "2.73%",
          "rating": "C"
        },
        {
          "name": "Net Profit YoY",
          "value": "-8.90%",
          "rating": "D"
        },
        {
          "name": "Total Assets YoY",
          "value": "8.72%",
          "rating": "B"
        },
        {
          "name": "Net Assets YoY",
          "value": "9.91%",
          "rating": "B"
        },
        {
          "name": "Cash Flow Margin",
          "value": "85.37%",
          "rating": "C"
        },
        {
          "name": "OCF YoY",
          "value": "2.73%",
          "rating": "C"
        },
        {
          "name": "Turnover",
          "value": "0.65",
          "rating": "B"
        },
        {
          "name": "Gearing Ratio",
          "value": "13.45%",
          "rating": "A"
        }
      ]
    }
  ]
}
```

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | 19.62 | 44/215 | 20.94 | 19.96 | 18.81 |
| PB | 2.52 | 116/215 | 3.18 | 3.03 | 2.83 |
| PS (TTM) | 3.51 | 95/215 | 4.23 | 4.01 | 3.79 |
| Dividend Yield | 0.00% | - | 1.61% | 1.52% | 1.44% |

## Peer Comparison

| Rank | Name | Profit | Growth | Operation | Security | Cash | Rating |
| --- | --- | --- | --- | --- | --- | --- | --- |
| 01 | Allist (688578.SH) | A | A | B | A | B | A |
| 02 | Xingqi Pharmaceutical (300573.SZ) | A | A | A | A | B | A |
| 03 | Hengrui Pharma (600276.SH) | A | B | C | A | B | B |
| 04 | Yunnan Baiyao (000538.SZ) | B | C | B | B | C | B |
| 05 | Haisco (002653.SZ) | A | A | B | B | B | B |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-21T16:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 2 | 40% |
| Overweight | 1 | 20% |
| Hold | 1 | 20% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 20.43 |
| Highest Target | 30.00 |
| Lowest Target | 23.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/002262.SZ/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/002262.SZ/norm.md)
- [Related News](https://longbridge.com/en/quote/002262.SZ/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/002262.SZ/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**